An Introduction to Catalytic Receptors
======================================

Catalytic receptors are cell-surface proteins, usually dimeric in nature, which typically encompass ligand binding and functional domains in one polypeptide chain. The ligand binding domain is placed on the extracellular surface of the plasma membrane and separated from the functional domain by a single transmembrane-spanning domain of 20-25 hydrophobic amino acids. The functional domain on the intracellular face of the plasma membrane has catalytic activity, or interacts with particular enzymes, giving the superfamily of receptors its name. Endogenous agonists of the catalytic receptor superfamily are peptides or proteins, the binding of which may induce dimerization of the receptor, which is the functional version of the receptor.

Amongst the catalytic receptors, particular subfamilies may be readily identified dependent on the function of the enzymatic portion of the receptor. The smallest group is the particulate guanylyl cyclases of the natriuretic peptide receptor family. The most widely recognized group is probably the receptor tyrosine kinase (RTK) family, epitomized by the neurotrophin receptor family, where a crucial initial step is the activation of a signalling cascade by autophosphorylation of the receptor on intracellular tyrosine residue(s) catalyzed by enzyme activity intrinsic to the receptor. A third group is the extrinsic protein tyrosine kinase receptors, where the catalytic activity resides in a separate protein from the binding site. Examples of this group include the GDNF receptor families, where one, catalytically silent, member of the heterodimer is activated upon binding the ligand, causing the second member of the heterodimer, lacking ligand binding capacity, to initiate signaling through tyrosine phosphorylation. A fourth group, the receptor threonine/serine kinase (RTSK) family, exemplified by TGF-β and BMP receptors, has intrinsic serine/threonine protein kinase activity in the heterodimeric functional unit. A fifth group is the receptor tyrosine phosphatases (RTP), which generally appear to lack cognate ligands, but may be triggered by events such as cell:cell contact and have identified roles in the skeletal, hematopoietic and immune systems.

A new group of catalytic receptors for the Guide is the integrins, which have roles in cell : cell communication, often associated with signalling in the blood.
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Cytokine receptor family
========================

Overview
--------

Cytokines are not a clearly defined group of agents, other than having an impact on immune signalling pathways, although many cytokines have effects on other systems, such as in development. A feature of some cytokines, which allows them to be distinguished from hormones, is that they may be produced by "non-secretory" cells, for example, endothelial cells. Within the cytokine receptor family, some subfamilies may be identified, which are described elsewhere in the Guide to PHARMACOLOGY, receptors for the TNF family, the TGF-β family and the chemokines. Within this group of records are described Type I cytokine receptors, typified by interleukin receptors, and Type II cytokine receptors, exemplified by interferon receptors. These receptors possess a conserved extracellular region, known as the cytokine receptor homology domain (CHD), along with a range of other structural modules, including extracellular immunoglobulin (Ig)-like and fibronectin type III (FBNIII)-like domains, a transmembrane domain, and intracellular homology domains. An unusual feature of this group of agents is the existence of soluble and decoy receptors. These bind cytokines without allowing signalling to occur. A further attribute is the production of endogenous antagonist molecules, which bind to the receptors selectively and prevent signalling. A commonality of these families of receptors is the ligand-induced homo- or hetero-oligomerisation, which results in the recruitment of intracellular protein partners to evoke cellular responses, particularly in inflammatory or haematopoietic signalling. Although not an exclusive signalling pathway, a common feature of the majority of cytokine receptors is activation of the JAK/STAT pathway. This cascade is based around the protein tyrosine kinase activity of the Janus kinases (JAK), which phosphorylate the receptor and thereby facilitate the recruitment of signal transducers and activators of transcription (STATs). The activated homo- or heterodimeric STATs function principally as transcription factors in the nucleus.

**Type I cytokine receptors** are characterized by two pairs of conserved cysteines linked via disulfide bonds and a C-terminal WSXWS motif within their CHD. Type I receptors are commonly classified into five groups, based on sequence and structual homology of the receptor and its cytokine ligand, which is potentially more reflective of evolutionary relationships than an earlier scheme based on the use of common signal transducing chains within a receptor complex.

IL-2 receptor family
====================

Overview
--------

The IL-2 receptor family consists of one or more ligand-selective subunits, and a common γ chain (γc): *IL2RG*, P31785), though IL-4 and IL-7 receptors can form complexes with other receptor chains. Receptors of this family associate with Jak1 and Jak3, primarily activating Stat5, although certain family members can also activate Stat1, Stat3, or Stat6. Ro264550 has been described as a selective IL-2 receptor antagonist, which binds to IL-2 [@b3].

  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  Nomenclature             Interleukin-2 receptor                                                                                                                                                   Interleukin-4 receptor type I                                                                       Interleukin-4 receptor type II                                                                 Interleukin-7 receptor                                                                              Interleukin-9 receptor
  Subunits                 Interleukin-2 receptor α subunit (Ligand-binding subunit), Interleukin-2 receptor β subunit (Ligand-binding subunit), Interleukin-2 receptor γ subunit (Other subunit)   Interleukin 4 receptor (Ligand-binding subunit), Interleukin-2 receptor γ subunit (Other subunit)   Interleukin 4 receptor (Ligand-binding subunit), Interleukin 13 receptor, α1 (Other subunit)   Interleukin 7 receptor (Ligand-binding subunit), Interleukin-2 receptor γ subunit (Other subunit)   Interleukin 9 receptor (Ligand-binding subunit), Interleukin-2 receptor γ subunit (Other subunit)
  Endogenous agonists      IL-2 (IL2, P60568)                                                                                                                                                       IL-4 (IL4, P05112)                                                                                  IL-13 (IL13, P35225), IL-4 (IL4, P05112)                                                       IL-7 (IL7, P13232)                                                                                  IL-9 (IL9, P15248)
  Endogenous antagonists   IL-1 receptor antagonist (IL1RN, P18510)                                                                                                                                 --                                                                                                  --                                                                                             --                                                                                                  --
  Selective antagonists    AF12198 [@b1], Ro264550 [@b3]                                                                                                                                            --                                                                                                  --                                                                                             --                                                                                                  --
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------

  --------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  Nomenclature          Interleukin 13 receptor, α2                                    Interleukin-15 receptor                                                                                                                                                    Interleukin-21 receptor                                                                              Thymic stromal lymphopoietin receptor
  HGNC, UniProt         IL13RA2, Q14627                                                --                                                                                                                                                                         --                                                                                                   --
  Subunits              --                                                             Interleukin-2 receptor β subunit (Ligand-binding subunit), Interleukin 15 receptor, α subunit (Ligand-binding subunit), Interleukin-2 receptor γ subunit (Other subunit)   Interleukin 21 receptor (Ligand-binding subunit), Interleukin-2 receptor γ subunit (Other subunit)   Interleukin 7 receptor (Ligand-binding subunit), Cytokine receptor-like factor 2 (Other subunit)
  Endogenous agonists   --                                                             IL-15 (IL15, P40933)                                                                                                                                                       IL-21 (IL21, Q9HBE4)                                                                                 TSLP (TSLP, Q969D9)
  Comment               Decoy receptor that binds IL-13 (IL13, P35225) as a monomer.   --                                                                                                                                                                         --                                                                                                   --
  --------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------

IL-3 receptor family
====================

Overview
--------

The IL-3 receptor family signal through a receptor complex comprising of a ligand-specific α subunit and a common β chain (*CSF2RB*, P32927), which is associated with Jak2 and signals primarily through Stat5.

  ----------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Nomenclature            Interleukin-3 receptor                                                                                           Interleukin-5 receptor                                                                                           Granulocyte macrophage colony-stimulating factor receptor
  Subunits                Interleukin 3 receptor, α subunit (Ligand-binding subunit), Cytokine receptor common β subunit (Other subunit)   Interleukin 5 receptor, α subunit (Ligand-binding subunit), Cytokine receptor common β subunit (Other subunit)   GM-CSF receptor, α subunit (Ligand-binding subunit), Cytokine receptor common β subunit (Other subunit)
  Endogenous agonists     IL-3 (IL3, P08700)                                                                                               IL-5 (IL5, P05113)                                                                                               G-CSF (CSF3, P09919), GM-CSF (CSF2, P04141)
  Selective antagonists   --                                                                                                               YM90709 [@b2]                                                                                                    --
  ----------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------

IL-6 receptor family
====================

Overview
--------

The IL-6 receptor family signal through a ternary receptor complex consisting of the cognate receptor and either the IL-6 signal transducer gp130 (*IL6ST*, P40189) or the oncostatin M-specific receptor, β subunit (*OSMR,* Q99650), which then activates the JAK/STAT, Ras/Raf/MAPK and PI 3-kinase/PKB signalling modules. Unusually amongst the cytokine receptors, the CNTF receptor is a glycerophosphatidylinositol-linked protein.

  --------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature          Interleukin-6 receptor                                                                                          Interleukin-11 receptor                                                                                          Interleukin-31 receptor                                                                                                  Ciliary neutrophic factor receptor
  Subunits              Interleukin-6 receptor, α subunit (Ligand-binding subunit), Interleukin-6 receptor, β subunit (Other subunit)   Interleukin-11 receptor, α subunit (Ligand-binding subunit), Interleukin-6 receptor, β subunit (Other subunit)   Interleukin-31 receptor, α subunit (Ligand-binding subunit), Oncostatin M-specific receptor, β subunit (Other subunit)   Ciliary neurotrophic factor receptor α subunit (Ligand-binding subunit), Leukemia inhibitory factor receptor (Other subunit), Interleukin-6 receptor, β subunit
  Endogenous agonists   IL-6 (IL6, P05231)                                                                                              IL-11 (IL11, P20809)                                                                                             IL-31 (IL31, Q6EBC2)                                                                                                     CNTF (CNTF, P26441), CRCF1/CLCF1 heterodimer (CRLF1, CLCF1, O75462, Q9UBD9)
  --------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Nomenclature          Leptin receptor        Leukemia inhibitory factor receptor                                                                               Oncostatin-M receptor                                                                                                   Interleukin-27 receptor
  HGNC, UniProt         LEPR, P48357           --                                                                                                                --                                                                                                                      --
  Subunits              --                     Leukemia inhibitory factor receptor (Ligand-binding subunit), Interleukin-6 receptor, β subunit (Other subunit)   Oncostatin M-specific receptor, β subunit (Ligand-binding subunit), Interleukin-6 receptor, β subunit (Other subunit)   Interleukin 27 receptor, alpha (Ligand-binding subunit), Interleukin-6 receptor, β subunit (Other subunit)
  Endogenous agonists   leptin (LEP, P41159)   CTF1 (CTF1, Q16619), LIF (LIF, P15018), OSM (OSM, P13725)                                                         OSM (OSM, P13725)                                                                                                       IL-27 (IL27, EBI3, Q14213, Q8NEV9)
  --------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------

IL-12 receptor family
=====================

Overview
--------

IL-12 receptors are a subfamily of the IL-6 receptor family. IL12RB1 is shared between receptors for IL-12 and IL-23; the functional agonist at IL-12 receptors is a heterodimer of IL-12A/IL-12B, while that for IL-23 receptors is a heterodimer of IL-12B/IL-23A.

Subunits 
---------

  --------------- ------------------------------------- -------------------------
  Nomenclature    Interleukin-12 receptor, β2 subunit   Interleukin 23 receptor
  HGNC, UniProt   IL12RB2, Q99665                       IL23R, Q5VWK5
  --------------- ------------------------------------- -------------------------

Prolactin receptor family
=========================

Overview
--------

Prolactin family receptors form homodimers in the presence of their respective ligands, associate exclusively with Jak2 and signal via Stat5.

  --------------------- ------------------------------ ------------------------------------------------ ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------------------
  Nomenclature          Eythropoietin receptor         Granulocyte colony-stimulating factor receptor   Growth hormone receptor                                          Prolactin receptor                                                                                                            Thrombopoietin receptor
  HGNC, UniProt         EPOR, P19235                   CSF3R, Q99062                                    GHR, P10912                                                      PRLR, P16471                                                                                                                  MPL, P40238
  Endogenous agonists   erythropoietin (EPO, P01588)   G-CSF (CSF3, P09919)                             growth hormone 1 (GH1, P01241), growth hormone 2 (GH2, P01242)   choriomammotropin (CSH1, CSH2, P01243), chorionic somatomammotropin hormone-like 1 (CSHL1, Q14406), prolactin (PRL, P01236)   thrombopoietin (THPO, P40225)
  --------------------- ------------------------------ ------------------------------------------------ ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------------------

**Type II cytokine receptors** also have two pairs of conserved cysteines but with a different arrangement to Type I and also lack the WSXWS motif.

Interferon receptor family
==========================

Overview
--------

The interferon receptor family includes receptors for type I (α, β κ and ω) and type II (γ) interferons. There are at least 13 different genesencoding IFN-&ALPHA; subunits in a cluster on human chromosome 9p22: α1 (*IFNA1*, P01562), α2 (*IFNA2*, P01563), α4 (*IFNA4*, P05014), α5 (*IFNA5*, P01569), α6 (*IFNA6*, P05013), α7 (*IFNA7*, P01567), α8 (*IFNA8*, P32881), α10 (*IFNA10*, P01566), α13 (*IFNA13*, P01562), α14 (*IFNA14*, P01570), α16 (*IFNA16*, P05015), α17 (*IFNA17*, P01571) and α21 (*IFNA21*, P01568).

  --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Nomenclature          Interferon-α/β receptor                                                                                                                                                                                                                                                                                                                                                                   Interferon-γ receptor
  Subunits              interferon α/β receptor 1 (Ligand-binding subunit), Interferon α/β receptor 2 (Other subunit)                                                                                                                                                                                                                                                                                             Interferon γ receptor 1 (Ligand-binding subunit), Interferon γ receptor 2 (Other subunit)
  Endogenous agonists   IFN-α10 (IFNA10, P01566), IFN-α1/13 (IFNA1, IFNA13, P01562), IFN-α14 (IFNA14, P01570), IFN-α16 (IFNA16, P05015), IFN-α17 (IFNA17, P01571), IFN-α2 (IFNA2, P01563), IFN-α21 (IFNA21, P01568), IFN-α4 (IFNA4, P05014), IFN-α5 (IFNA5, P01569), IFN-α6 (IFNA6, P05013), IFN-α7 (IFNA7, P01567), IFN-α8 (IFNA8, P32881), IFN-β (IFNB1, P01574), IFN-κ (IFNK, Q9P0W0), IFN-ω (IFNW1, P05000)   IFN-γ (IFNG, P01579)
  --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------

IL-10 receptor family
=====================

Overview
--------

The IL-10 family of receptors are heterodimeric combinations of family members: IL10RA/IL10RB responds to IL-10; IL20RA/IL20RB responds to IL-19, IL-20 and IL-24; IL22RA1/IL20RB responds to IL-20 and IL-24; IL22RA1/IL10RB responds to IL-22; IL28RA/IL10RB responds to IL-28A, IL28B and IL-29.

  --------------------- ----------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Nomenclature          Interleukin-10 receptor                                                                                           Interleukin-20 receptor                                                                                           Interleukin-22α1/20β heteromer                                                                                              Interleukin-22α1/10β heteromer                                                                                              Interleukin-22 receptor α2                                            Interferon-λ receptor 1
  HGNC, UniProt         --                                                                                                                --                                                                                                                --                                                                                                                          --                                                                                                                          IL22RA2, Q969J5                                                       --
  Subunits              Interleukin 10 receptor, α subunit (Ligand-binding subunit), Interleukin 10 receptor, β subunit (Other subunit)   Interleukin 20 receptor, α subunit (Ligand-binding subunit), Interleukin 20 receptor, β subunit (Other subunit)   Interleukin 20 receptor, β subunit (Ligand-binding subunit), Interleukin 22 receptor, α1 subunit (Ligand-binding subunit)   Interleukin 10 receptor, β subunit (Ligand-binding subunit), Interleukin 22 receptor, α1 subunit (Ligand-binding subunit)   --                                                                    Interferon-λ receptor 1 (Ligand-binding subunit), Interleukin 10 receptor, β subunit (Other subunit)
  Endogenous agonists   IL-10 (IL10, P22301)                                                                                              IL-19 (IL19, Q9UHD0), IL-20 (IL20, Q9NYY1), IL-24 (IL24, Q13007)                                                  IL-20 (IL20, Q9NYY1), IL-24 (IL24, Q13007)                                                                                  IL-22 (IL22, Q9GZX6)                                                                                                        --                                                                    IFN-λ1 (IFNL1, Q8IU54), IFN-λ2 (IFNL2, Q8IZJ0), IFN-λ3 (IFNL3, Q8IZI9)
  Comment               --                                                                                                                --                                                                                                                --                                                                                                                          --                                                                                                                          Soluble decoy receptor that binds IL-22 (IL22, Q9GZX6) as a monomer   --
  --------------------- ----------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------

Immunoglobulin-like family of IL-1 receptors
============================================

Overview
--------

The immunoglobulin-like family of IL-1 receptors are heterodimeric receptors made up of a cognate receptor subunit and an IL-1 receptor accessory protein, IL1RAP (Q9NPH3, also known as C3orf13, IL-1RAcP, IL1R3). They are characterised by extracellular immunoglobulin-like domains and an intracellular Toll/Interleukin-1R (TIR) domain.

  ------------------------ ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Nomenclature             Interleukin-1 receptor, type I                                                                             Interleukin-33 receptor                                                                                   Interleukin-36 receptor                                                                                                Interleukin-1 receptor, type II                                                                                     Interleukin-18 receptor
  Subunits                 Interleukin 1 receptor, type I (Ligand-binding subunit), IL-1 receptor accessory protein (Other subunit)   Interleukin-1 receptor-like 1 (Ligand-binding subunit), IL-1 receptor accessory protein (Other subunit)   Interleukin-1 receptor-like 2 (Ligand-binding subunit), IL-1 receptor accessory protein (Other subunit)                Interleukin 1 receptor, type II (Ligand-binding subunit), IL-1 receptor accessory protein (Other subunit)           Interleukin-18 1 (Ligand-binding subunit), IL-18 receptor accessory protein (Other subunit)
  Endogenous agonists      IL-1α (IL1A, P01583), IL-1β (IL1B, P01584)                                                                 IL-33 (IL33, O95760)                                                                                      IL-36α (IL36A, Q9UHA7), IL-36β (IL36B, Q9NZH7), IL-36γ (IL36G, Q9NZH8),                                                --                                                                                                                  IL-18 (IL18, Q14116), IL-37 (IL37, Q9NZH6)
  Endogenous antagonists   IL-1 receptor antagonist (IL1RN, P18510)                                                                   --                                                                                                        IL-36 receptor antagonist (IL36RN, Q9UBH0)                                                                             --                                                                                                                  --
  Selective antagonists    AF12198 [@b1]                                                                                              --                                                                                                        --                                                                                                                     --                                                                                                                  --
  Comment                  --                                                                                                         --                                                                                                        IL-36 receptor antagonist (IL36RN, Q9UBH0) is a highly specific antagonist of the response to IL-36γ (IL36G, Q9NZH8)   Decoy receptor that binds IL-1α (IL1A, P01583), IL-1β (IL1B, P01584) and IL-1 receptor antagonist (IL1RN, P18510)   --
  ------------------------ ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------

IL-17 receptor family
=====================

Overview
--------

The IL17 cytokine family consists of six ligands (IL-17A-F), which signal through five receptors (IL-17RA-E).

  --------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -----------------------------------------------------
  Nomenclature          Interleukin-17 receptor                                                                         Interleukin-25 receptor                                                                         Interleukin-17C receptor                                                                        Interleukin-17 receptor D
  HGNC, UniProt         --                                                                                              --                                                                                              --                                                                                              IL17RD, Q8NFM7
  Subunits              Interleukin 17 receptor A (Ligand-binding subunit), interleukin 17 receptor C (Other subunit)   Interleukin 17 receptor B (Ligand-binding subunit), Interleukin 17 receptor A (Other subunit)   Interleukin 17 receptor E (Ligand-binding subunit), Interleukin 17 receptor A (Other subunit)   --
  Endogenous agonists   IL-17A (IL17A, Q16552), IL-17A/IL-17F (IL17F, IL17A, Q16552, Q96PD4), IL-17F (IL17F, Q96PD4)    IL-17B (IL17B, Q9UHF5), IL-25 (IL25, Q9H293)                                                    IL-17C (IL17C, Q9P0M4)                                                                          The endogenous agonist for this receptor is unknown
  --------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -----------------------------------------------------

GDNF receptor family
====================

Overview
--------

GDNF family receptors (provisional nomenclature) are extrinsic tyrosine kinase receptors. Ligand binding to the extracellular domain of the glycosylphosphatidylinositol-linked cell-surface receptors (tabulated below) activates a transmembrane tyrosine kinase enzyme, RET (see Receptor Tyrosine Kinases). The endogenous ligands are typically dimeric, linked through disulphide bridges: glial cell-derived neurotrophic factor GDNF (GDNF, P39905) (211 aa); neurturin NRTN (NRTN, Q99748), 197 aa); artemin (ARTN (ARTN, Q5T4W7), 237 aa) and PSPN (PSPN, O60542) (PSPN, 156 aa).

  ----------------------- ------------------------------------------------------------------- -------------------------------------------- ------------------------- -------------------------
  Nomenclature            GDNF family receptor α1                                             GDNF family receptor α2                      GDNF family receptor α3   GDNF family receptor α4
  Common abbreviation     GFRα1                                                               GFRα2                                        GFRα3                     GFRα4
  HGNC, UniProt           GFRA1, P56159                                                       GFRA2, O00451                                GFRA3, O60609             GFRA4, Q9GZZ7
  Potency order           GDNF (GDNF, P39905) \> NRTN (NRTN, Q99748) \> ARTN (ARTN, Q5T4W7)   NRTN (NRTN, Q99748) \> GDNF (GDNF, P39905)   ARTN (ARTN, Q5T4W7)       PSPN (PSPN, O60542)
  Radioligands (*K*~d~)   \[125I\]GDNF (rat) (3x10^-12^ -- 6.3x10^-11^ M) [@b4],[@b6]         --                                           --                        --
  ----------------------- ------------------------------------------------------------------- -------------------------------------------- ------------------------- -------------------------

Comments
========

Inhibitors of other receptor tyrosine kinases, such as semaxinib, which inhibits VEGF receptor function, may also inhibit Ret function [@b5]. Mutations of RET and GDNF genes may be involved in Hirschsprung\'s disease, which is characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction.

Integrins
=========

Overview
--------

Integrins (provisional nomenclature) are heterodimeric entities, composed of α and β subunits, each 1TM proteins, which bind components of the extracellular matrix or counter-receptors expressed on other cells. One class of integrin contains an inserted domain (I) in its α subunit, and if present (in α1, α2, α10, α11, αD, αE, αL, αM and αX), this I domain contains the ligand binding site. All β subunits possess a similar I-like domain, which has the capacity to bind ligand, often recognising the RGD motif. The presence of an α subunit I domain precludes ligand binding through the β subunit. Integrins provide a link between ligand and the actin cytoskeleton (through typically short intracellular domains). Integrins bind several divalent cations, including a Mg^2+^ atom in the I or I-like domain that is essential for ligand binding. Other cation binding sites may regulate integrin activity or stabilise the 3D structure. Integrins regulate the activity of particular protein kinases, including focal adhesion kinase and integrin-linked kinase. Cellular activation regulates integrin ligand affinity via inside-out signalling and ligand binding to integrins can regulate cellular activity via outside-in signalling.

  -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------
  Nomenclature   Subunits                                                                                                                                                                                    Ligands                                                                                              Selective inhibitors (pIC~50~)                                                         Comment
  α1β1           integrin, alpha 1 subunit, integrin, beta 1 subunit (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)                                                             collagen, laminin                                                                                    obtustatin (9.1) [@b11]                                                                --
  α2β1           integrin, alpha 2 subunit (CD49B, alpha 2 subunit of VLA-2 receptor), integrin, beta 1 subunit (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)                  collagen, laminin, thrombospondin                                                                    TCI15 (7.9) [@b13]                                                                     --
  αIIbβ3         integrin, alpha 2b subunit (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41), integrin, beta 3 subunit (platelet glycoprotein IIIa, antigen CD61)                               fibrinogen, fibronectin, von Willebrand factor, vitronectin, thrombospondin                          abciximab, eptifibatide, G4120 [@b12], GR144053, Syk inhibitor III [@b14], tirofiban   --
  α4β1           integrin, alpha 4 subunit (antigen CD49D, alpha 4 subunit of VLA-4 receptor), integrin, beta 1 subunit (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)          fibronectin, VCAM-1, osteopontin, thrombospondin                                                     natalizumab, TCS2314, BIO1211 (8.3 -- 9.0) [@b9]                                       LDV-FITC is used as a probe at this receptor
  αLβ2           integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide), integrin, beta 2 subunit (complement component 3 receptor 3 and 4 subunit)   ICAM-1, ICAM-2                                                                                       efalizumab, A286982 (7.4 -- 7.5) [@b10]                                                --
  αVβ3           integrin, alpha V subunit, integrin, beta 3 subunit (platelet glycoprotein IIIa, antigen CD61)                                                                                              vitronectin, fibronectin, fibrinogen, osteopontin, von Willebrand factor, thrombospondin, tenascin   etaracizumab, echistatin (11.7) [@b8], P11 (11.6) [@b8], cilengitide (8.5) [@b7]       --
  -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------

Subunits
========

  --------------------------------------------------------------------------------------------------------------- ----------------
  Nomenclature                                                                                                    HGNC, UniProt
  integrin, alpha 1 subunit                                                                                       ITGA1, P56199
  integrin, alpha 2 subunit (CD49B, alpha 2 subunit of VLA-2 receptor)                                            ITGA2, P08514
  integrin, alpha 2b subunit (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41)                        ITGA2B, P17301
  integrin, alpha 3 subunit (antigen CD49C, alpha 3 subunit of VLA-3 receptor)                                    ITGA3, P26006
  integrin, alpha 4 subunit (antigen CD49D, alpha 4 subunit of VLA-4 receptor)                                    ITGA4, P13612
  integrin, alpha 5 subunit (fibronectin receptor, alpha polypeptide)                                             ITGA5, P08648
  integrin, alpha 6 subunit                                                                                       ITGA6, P23229
  integrin, alpha 7 subunit                                                                                       ITGA7, Q13683
  integrin, alpha 8 subunit                                                                                       ITGA8, P53708
  integrin, alpha 9 subunit                                                                                       ITGA9, Q13797
  integrin, alpha 10 subunit                                                                                      ITGA10, O75578
  integrin, alpha 11 subunit                                                                                      ITGA11, Q9UKX5
  integrin, alpha D subunit                                                                                       ITGAD, Q13349
  integrin, alpha E subunit (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)                ITGAE, P38570
  integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)   ITGAL, P20701
  integrin, alpha M subunit (complement component 3 receptor 3 subunit)                                           ITGAM, P11215
  integrin, alpha V subunit                                                                                       ITGAV, P06756
  integrin, alpha X subunit (complement component 3 receptor 4 subunit)                                           ITGAX, P20702
  --------------------------------------------------------------------------------------------------------------- ----------------

  ------------------------------------------------------------------------------------------------------ ---------------
  Nomenclature                                                                                           HGNC, UniProt
  integrin, beta 1 subunit (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)   ITGB1, P05556
  integrin, beta 2 subunit (complement component 3 receptor 3 and 4 subunit)                             ITGB2, P05107
  integrin, beta 3 subunit (platelet glycoprotein IIIa, antigen CD61)                                    ITGB3, P05106
  integrin, beta 4 subunit                                                                               ITGB4, P16144
  integrin, beta 5 subunit                                                                               ITGB5, P18084
  integrin, beta 6 subunit                                                                               ITGB6, P18564
  integrin, beta 7 subunit                                                                               ITGB7, P26010
  integrin, beta 8 subunit                                                                               ITGB8, P26012
  ------------------------------------------------------------------------------------------------------ ---------------

Integrin ligands
================

**Collagen** is the most abundant protein in metazoa, rich in glycine and proline residues, made up of cross-linked triple helical structures, generated primarily by fibroblasts. Extensive post-translational processing is conducted by prolyl and lysyl hydroxylases, as well as transglutaminases. Over 40 genes for collagen-α subunits have been identified in the human genome. The collagen-binding integrins α1β1, α2β1, α10β1 and α11β1 recognise a range of triple-helical peptide motifs including GFOGER (O = hydroxyproline), a synthetic peptide.

**Laminin** is an extracellular glycoprotein composed of α, β and γ chains, for which five, four and three genes, respectively, are identified in the human genome. It binds to α1β1, α2β1, α3,β1, α7β1 and α6β4 integrins10.

**Fibrinogen** is a glycosylated hexamer composed of two α (FGA, P02671), two β (FGB, P02675) and two γ (FGG, P02679,) subunits, linked by disulphide bridges. It is found in plasma and alpha granules of platelets. It forms cross-links between activated platelets mediating aggregation by binding αIIbβ3; proteolysis by thrombin cleaves short peptides termed fibrinopeptides to generate fibrin, which polymerises as part of the blood coagulation cascade.

**Fibronectin** is a disulphide-linked homodimer found as two major forms; a soluble dimeric form found in the plasma and a tissue version that is polymeric, which is secreted into the extracellular matrix by fibroblasts. Splice variation of the gene product (FN1, P02751) generates multiple isoforms.

**Vitronectin** is a serum glycoprotein and extracellular matrix protein (VTN, P04004) which is found either as a monomer or, following proteolysis, a disulphide -linked dimer.

**Osteopontin** forms an integral part of the mineralized matrix in bone (SPP1, P10451), where it undergoes extensive post-translation processing, including proteolysis and phosphorylation.

**Von Willebrand factor** (VWF, P04275) is a glycoprotein synthesised in vascular endothelial cells as a disulphide-linked homodimer, but multimerises further in plasma and is deposited on vessel wall collagen as a high molecular weight multimer. It is responsible for capturing platelets under arterial shear flow (*via* GPIb) and in thrombus propagation (via integrin αIIbβ3).

Natriuretic peptide receptor family
===================================

Overview
--------

Natriuretic peptide receptors (provisional nomenclature) are a family of homodimeric, catalytic receptors with a single TM domain and guanylyl cyclase (EC 4.6.1.2) activity on the intracellular domain of the protein sequence. Isoforms are activated by the peptide hormones atrial natriuretic peptide (ANP (NPPA, P01160)), brain natriuretic peptide (BNP (NPPB, P16860)) and C-type natriuretic peptide (CNP (NPPC, P23582)). Another family member is GC-C, the receptor for guanylin (GUCA2A, Q02747) and uroguanylin (GUCA2B, Q16661). Family members have conserved ligand-binding, catalytic (guanylyl cyclase) and regulatory domains with the exception of NPR-C which has an extracellular binding domain homologous to that of other NPRs, but with a truncated intracellular domain which appears to couple, via the G~i/o~ family of G-proteins, to activation of phospholipase C, inwardly-rectifying potassium channels and inhibition of adenylyl cyclase activity [@b25].

  ----------------------- ----------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------- -----------------------------------------------------------
  Nomenclature            NPR-A                                                                                                 NPR-B                                                                       NPR-C                                                                  guanylate cyclase 2C (heat stable enterotoxin receptor)
  HGNC, UniProt           NPR1, P16066                                                                                          NPR2, P20594                                                                NPR3, P17342                                                           GUCY2C, P25092
  Potency order           ANP (NPPA, P01160) ≥ BNP (NPPB, P16860) \>\> CNP (NPPC, P23582) [@b27]                                CNP (NPPC, P23582) \>\> ANP (NPPA, P01160) \>\> BNP (NPPB, P16860) [@b27]   ANP (NPPA, P01160) \> CNP (NPPC, P23582) ≥ BNP (NPPB, P16860) [@b27]   uroguanylin (GUCA2B, Q16661) \> guanylin (GUCA2A, Q02747)
  Endogenous agonists     ANP (NPPA, P01160) (Selective) [@b26], BNP (NPPB, P16860) (Selective) [@b26]                          CNP (NPPC, P23582) (Selective) [@b27]                                       osteocrin (OSTN, P61366) (Selective) [@b23]                            --
  Selective agonists      sANP [@b26]                                                                                           --                                                                          cANF4-23 [@b22]                                                        E. coli heat-stable enterotoxin (STa), linaclotide [@b18]
  Selective antagonists   anantin [@b29], A-71915 (p*K*~i~ 9.2 -- 9.5) [@b15], \[Asu7,23\'\]β-ANP-(7-28) (p*K*~i~ 7.5) [@b21]   monoclonal antibody 3G12 [@b17], \[Ser11\](N-CNP,C-ANP)pBNP2-15 [@b16]      M372049 [@b19], AP811 (p*K*~i~ 9.3) [@b28]                             --
  Radioligands (*K*~d~)   \[125I\]ANP                                                                                           \[125I\]CNP (human)                                                         \[125I\]ANP                                                            \[125I\]Sta
  ----------------------- ----------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------- -----------------------------------------------------------

Comments
========

The polysaccharide obtained from fermentation of Aureobasidium species, HS142-1, acts as an antagonist at both NPR-A and NPR-B receptors [@b24]. GUCY2D (RetGC1, GC-E, Q02846) and GUCY2F (RetGC2, GC-F, P51841) are predominantly retinal guanylyl cyclase activities, which are inhibited by calcium ions acting through the guanylyl cyclase activating peptides GCAP1 (GUCA1A, 43080), GCAP2 (GUCA1B, Q9UMX6) and GCAP3 (GUCA1C, O95843) [@b20].

Pattern Recognition receptors
=============================

Overview
--------

Pattern recognition receptors (PRR, [@b42]) participate in the innate immune response to microbial agents, the stimulation of which leads to activation of intracellular enzymes and regulation of gene transcription. PRR include both cell-surface and intracellular proteins, including toll-like receptors (TLR), nucleotide-binding oligomerization domain-like receptors (NLR, also known as NOD-like receptors) and the mannose receptor family (ENSFM00250000004089). PRR may be divided into signalling-associated members, identified here, and endocytic members (such as the mannose receptor family), the function of which appears to be to recognise particular microbial motifs for subsequent cell attachment, internalisation and destruction.

PRRs express multiple leucine-rich regions to bind a range of microbially-derived ligands, termed PAMPs or pathogen-associated molecular patterns, which includes peptides, carbohydrates, peptidoglycans, lipoproteins, lipopolysaccharides, and nucleic acids.

Toll-like receptor family
=========================

Overview
--------

Members of this family share significant homology with the interleukin-1 receptor family and appear to require dimerization either as homo- or heterodimers for functional activity. Heterodimerization appears to influence the potency of ligand binding substantially (*e.g.* TLR1/2 and TLR2/6, [@b43],[@b44]). TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are cell-surface proteins, while other members are associated with intracellular organelles, signalling through the MyD88-dependent pathways (with the exception of TLR3). As well as responding to exogenous infectious agents, it has been suggested that selected members of the family may be activated by endogenous ligands, such as hsp60 (HSPD1, P10809) [@b38].

  -------------- --------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Agonists                                           Comment
  TLR1           TLR1, Q15399    --                                                 --
  TLR2           TLR2, O60603    peptidoglycan [@b41],[@b45]                        --
  TLR3           TLR3, O15455    polyIC [@b30]                                      --
  TLR4           TLR4, O00206    LPS [@b39], taxol [@b36]                           eritoran (E5564) is a lipid A analogue, which has been described as a TLR4 antagonist [@b35]
  TLR5           TLR5, O60602    flagellin [@b31]                                   --
  TLR6           TLR6, Q9Y2C9    --                                                 --
  TLR7           TLR7, Q9NYK1    imiquimod [@b33], loxoribine [@b32], R848 [@b33]   --
  TLR8           TLR8, Q9NR97    imiquimod, R848 [@b33]                             --
  TLR9           TLR9, Q9NR96    CpG [@b34]                                         --
  TLR10          TLR10, Q9BXR5   --                                                 --
  TLR11          --, Q6R5P0      --                                                 Found in the mouse
  -------------- --------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------

NOD-like receptor family
========================

Overview
--------

Structural analysis has identified a common motif of a mid-peptide located nucleotide-binding and oligomerization (NACHT) domain, which allows division of NOD-like receptors into three subfamilies, NLRC (or NODs), NLRP (or NALP) and IPAF [@b40]. NLRC members are named on the basis of a sequence motif expressed at their N-termini, the caspase recruitment domain (CARD), while NLRP members have a pyrin domain. NLRs express C-terminal leucine-rich regions which have regulatory function and appear to recognize the microbial products to which the NLRs respond. NLRC family members recruit a serine/threonine kinase RIPK2 (receptor-interacting serine/threonine kinase 2, O43353, also known as CARD3, CARDIAK, RICK, RIP2) leading to signalling through NFκB and MAP kinase. NLRP family members, upon activation, recruit adaptor proteins (*e.g.* ASC, also known as PYCARD, CARD5, TMS-1, Q9ULZ3). Activated NLRs associate in multiprotein complexes, known as inflammasomes [@b40], allowing the recruitment of caspases.

  -------------- ---------------- ------------------- ---------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt    Agonists            Comment
  NLRC1          NOD1, Q9Y239     meso-DAP            --
  NLRC2          NOD2, Q9HC29     muramyl dipeptide   --
  NLRC3          NLRC3, Q7RTR2    --                  --
  NLRC5          NLRC5, Q86WI3    --                  --
  NLRX1          NLRX1, Q86UT6    --                  --
  CIITA          CIITA, P33076    --                  --
  NLRP1          NLRP1, Q9C000    muramyl dipeptide   --
  NLRP2          NLRP2, Q9NX02    --                  --
  NLRP3          NLRP3, Q96P20    --                  Multiple virus particles have been shown to act as agonists, including Sendai and influenza
  NLRP4          NLRP4, Q96MN2    --                  --
  NLRP5          NLRP5, P59047    --                  --
  NLRP6          NLRP6, P59044    --                  --
  NLRP7          NLRP7, Q8WX94    --                  --
  NLRP8          NLRP8, Q86W28    --                  --
  NLRP9          NLRP9, Q7RTR0    --                  --
  NLRP10         NLRP10, Q86W26   --                  --
  NLRP11         NLRP11, P59045   --                  --
  NLRP12         NLRP12, P59046   --                  --
  NLRP13         NLRP13, Q86W25   --                  --
  NLRP14         NLRP14, Q86W24   --                  --
  IPAF           NLRC4, Q9NPP4    --                  --
  NAIP           NAIP, Q13075     --                  --
  -------------- ---------------- ------------------- ---------------------------------------------------------------------------------------------

Comments
--------

NLRP3 has also been reported to respond to host-derived products, known as danger-associated molecular patterns, or DAMPs, including uric acid [@b37], ATP, L-glucose, hyaluronan and amyloid β (APP, P05067) [@b40].

Loss-of-function mutations of NLRP3 are associated with cold autoinflammatory and Muckle-Wells syndromes.

Receptor serine/threonine kinase (RSTK) family
==============================================

Overview
--------

Receptor serine/threonine kinases (RTSK), EC 2.7.11.30, respond to particular cytokines, the transforming growth factor β (TGFβ) and bone morphogenetic protein (BMP) families, and may be divided into two subfamilies on the basis of structural similarities. Agonist binding initiates formation of a cell-surface complex of type I and type II RSTK, possibly heterotetrameric, where where both subunits express serine/threonine kinase activity. The type I receptor serine/threonine kinases (ENSFM00250000000213) are also known as activin receptors or activin receptor-like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1-7). The type II protein phosphorylates the kinase domain of the type I partner (sometimes referred to as the signal propagating subunit), causing displacement of the protein partners, such as the FKBP12 FK506-binding protein FKBP1A (P62942) and allowing the binding and phosphorylation of particular members of the Smad family. These migrate to the nucleus and act as complexes to regulate gene transcription. Type III receptors, sometimes called co-receptors or accessory proteins, regulate the signalling of the receptor complex, in either enhancing (for example, presenting the ligand to the receptor) or inhibitory manners. TGFβ family ligand signalling may be inhibited by endogenous proteins, such as follistatin (FST, P19883), which binds and neutralizes activins to prevent activation of the target receptors.

Endogenous agonists, approximately 30 in man, are often described as paracrine messengers acting close to the source of production. They are characterized by six conserved cysteine residues and are divided into two subfamilies on the basis of sequence comparison and signalling pathways activated, the TGFβ/activin/nodal subfamily and the BMP/GDF (growth/differentiation factor)/MIS (Müllerian inhibiting substance) subfamily. Ligands active at RSTKs appear to be generated as large precursors which undergo complex maturation processes [@b47]. Some are known to form disulphide-linked homo- and/or heterodimeric complexes. Thus, inhibins are α subunits linked to a variety of β chains, while activins are combinations of β subunits.

Type I receptor serine/threonine kinases
========================================

Overview
--------

The type I receptor serine/threonine kinases (ENSFM00250000000213) are also known as activin receptors or activin receptor-like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1-7).

  --------------------- ----------------------------------- ---------------------------- ---------------------------------------------- ----------------------------- --------------------------------------------- ---------------------------------------------- -----------------------------
  Nomenclature          activin A receptor type II-like 1   activin A receptor, type I   bone morphogenetic protein receptor, type IA   activin A receptor, type IB   transforming growth factor, beta receptor 1   bone morphogenetic protein receptor, type IB   activin A receptor, type IC
  Common abbreviation   ALK1                                ALK2                         BMPR1A                                         ALK4                          TGFBR1                                        BMPR1B                                         ALK7
  HGNC, UniProt         ACVRL1, P37023                      ACVR1, Q04771                BMPR1A, P36894                                 ACVR1B, P36896                TGFBR1, P36897                                BMPR1B, O00238                                 ACVR1C, Q8NER5
  --------------------- ----------------------------------- ---------------------------- ---------------------------------------------- ----------------------------- --------------------------------------------- ---------------------------------------------- -----------------------------

Type II receptor serine/threonine kinases
=========================================

  --------------------- ------------------------------ ------------------------------ ------------------------------------------ ------------------------------------------------------------------------ ---------------------------------------------------------
  Nomenclature          activin A receptor, type IIA   activin A receptor, type IIB   anti-Mullerian hormone receptor, type II   bone morphogenetic protein receptor, type II (serine/threonine kinase)   transforming growth factor, beta receptor II (70/80kDa)
  Common abbreviation   ActR2                          ActR2B                         MISR2                                      BMPR2                                                                    TGFBR2
  HGNC, UniProt         ACVR2A, P27037                 ACVR2B, Q13705                 AMHR2, Q16671                              BMPR2, Q13873                                                            TGFBR2, P37173
  --------------------- ------------------------------ ------------------------------ ------------------------------------------ ------------------------------------------------------------------------ ---------------------------------------------------------

Type III receptor serine/threonine kinases
==========================================

  --------------------- -----------------------------------------------
  Nomenclature          transforming growth factor, beta receptor III
  Common abbreviation   TGFBR3
  HGNC, UniProt         TGFBR3, Q03167
  --------------------- -----------------------------------------------

RSTK functional heteromers
==========================

  --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature          Transforming growth factor β receptor                                                                                                                                               Bone morphogenetic protein receptors                                                                                                                                                                                                                                                                                                                              Growth/differentiation factor receptors                                                                                                                                                                                                                                                                                                                                                                            Activin receptors                                                                                                                                            Anti-Müllerian hormone receptors
  Subunits              transforming growth factor, beta receptor 1 (Type I), transforming growth factor, beta receptor II (70/80kDa) (Type II), transforming growth factor, beta receptor III (Type III)   activin A receptor type II-like 1 (Type I), activin A receptor, type I (Type I), bone morphogenetic protein receptor, type IA (Type I), bone morphogenetic protein receptor, type IB (Type I), activin A receptor, type IIA (Type II), activin A receptor, type IIB (Type II), bone morphogenetic protein receptor, type II (serine/threonine kinase) (Type II)   bone morphogenetic protein receptor, type IA (Type I), activin A receptor, type IB (Type I), transforming growth factor, beta receptor 1 (Type I), bone morphogenetic protein receptor, type IB (Type I), activin A receptor, type IC (Type I), activin A receptor, type IIA (Type II), activin A receptor, type IIB (Type II), bone morphogenetic protein receptor, type II (serine/threonine kinase) (Type II)   activin A receptor, type IB (Type I), activin A receptor, type IC (Type I), activin A receptor, type IIA (Type II), activin A receptor, type IIB (Type II)   activin A receptor, type I (Type I), bone morphogenetic protein receptor, type IA (Type I), bone morphogenetic protein receptor, type IB (Type I), anti-Mullerian hormone receptor, type II (Type II)
  Coupling              Smad2, Smad3 [@b48],[@b49]                                                                                                                                                          Smad1, Smad5, Smad8 [@b48],[@b49]                                                                                                                                                                                                                                                                                                                                 Smad1, Smad5, Smad8 [@b48],[@b49]                                                                                                                                                                                                                                                                                                                                                                                  Smad2, Smad3 [@b49]                                                                                                                                          Smad1, Smad5, Smad8 [@b48],[@b49]
  Endogenous agonists   TGFβ1 (TGFB1, P01137), TGFβ2 (TGFB2, P61812), TGFβ3 (TGFB3, P10600)                                                                                                                 BMP-10 (BMP10, O95393), BMP-2 (BMP2, P12643), BMP-4 (BMP4, P12644), BMP-5 (BMP5, P22003), BMP-6 (BMP6, P22004), BMP-7 (BMP7, P18075), BMP-8A (BMP8A, Q7Z5Y6), BMP-8B (BMP8B, P34820), BMP-9 (GDF2, Q9UK05)                                                                                                                                                        GDF1 (GDF1, P27539), GDF10 (GDF10, P55107), GDF9 (GDF9, O60383), GDF3 (GDF3, Q9NR23)                                                                                                                                                                                                                                                                                                                               inhibin βA (INHBA, P08476), inhibin βB (INHBB, P09529)                                                                                                       Müllerian inhibiting substance (AMH, P03971)
  --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

A number of endogenous inhibitory ligands have been identified for RSTKs, including BMP3, inhibinα, inhibinβC and inhibinβE.

An appraisal of small molecule inhibitors of TGFβ and BMP signalling concluded that TGFβ pathway inhibitors were more selective than BMP signalling inhibitors [@b50]. The authors confirmed the selectivity of SB505124 to inhibit TGFβ signalling through ALK4, ALK5, ALK7 [@b46]. dorsomorphin inhibits BMP signalling through ALK2 and ALK3, it also inhibits AMP kinase [@b51].

**Smads** were identified as mammalian orthologues of Drosophila genes termed "mothers against decapentaplegic" and may be divided into Receptor-regulated Smads (R-Smads, including Smad1, Smad2, Smad3, Smad5 and Smad8), Co-mediated Smad (Co-Smad, Smad4) and Inhibitory Smads (I-Smad, Smad6 and Smad7). R-Smads form heteromeric complexes with Co-Smad. I-Smads compete for binding of R-Smad with both receptors and Co-Smad.

  -------------- --------------- -------------------------
  Nomenclature   HGNC, UniProt   Other names
  Smad1          SMAD1, Q15797   JV4-1, MADH1, MADR1
  Smad2          SMAD2, Q15796   JV18-1, MADH2, MADR2
  Smad3          SMAD3, P84022   HsT17436, JV15-2, MADH3
  Smad4          SMAD4, Q13485   DPC4, MADH4
  Smad5          SMAD5, Q99717   Dwfc, JV5-1, MADH5
  Smad6          SMAD6, O43541   HsT17432, MADH6, MADH7
  Smad7          SMAD7, O15105   MADH7, MADH8
  Smad8          SMAD9, O15198   MADH6, MADH9
  -------------- --------------- -------------------------

Receptor tyrosine kinases
=========================

Overview
--------

Receptor tyrosine kinases (RTKs, EC 2.7.10.1), a family of cell-surface receptors, which transduce signals to polypeptide and protein hormones, cytokines and growth factors are key regulators of critical cellular processes, such as proliferation and differentiation, cell survival and metabolism, cell migration and cell cycle control [@b55],[@b65],[@b82]. In the human genome, 58 RTKs have been identified, which fall into 20 families [@b70].

All RTKs display an extracellular ligand binding domain, a single transmembrane helix, a cytoplasmic region containing the protein tyrosine kinase activity (occasionally split into two domains by an insertion, termed the kinase insertion), with juxta-membrane and C-terminal regulatory regions. Agonist binding to the extracellular domain evokes dimerization, and sometimes oligomerization, of RTKs (a small subset of RTKs forms multimers even in the absence of activating ligand). This leads to autophosphorylation in the tyrosine kinase domain in a trans orientation, serving as a site of assembly of protein complexes and stimulation of multiple signal transduction pathways, including phospholipase C-γ, mitogen-activated protein kinases and phosphatidylinositol 3-kinase [@b82].

RTKs are of widespread interest not only through physiological functions, but also as drug targets in many types of cancer and other disease states. Many diseases result from genetic changes or abnormalities that either alter the activity, abundance, cellular distribution and/or regulation of RTKs. Therefore, drugs that modify the dysregulated functions of these RTKs have been developed which fall into two categories. One group is often described as 'biologicals\', which block the activation of RTKs directly or by chelating the cognate ligands, while the second are small molecules designed to inhibit the tyrosine kinase activity directly.

Type I RTKs: ErbB (epidermal growth factor) receptor family
===========================================================

Overview
--------

ErbB family receptors are Class I receptor tyrosine kinases [@b65]. ERBB2 (also known as HER-2 or NEU; *ERBB2*, P04626) appears to act as an essential partner for the other members of the family without itself being activated by a cognate ligand [@b66]. Ligands of the ErbB family of receptors are peptides, many of which are generated by proteolytic cleavage of cell-surface proteins. HER/ErbB is the viral counterpart to the receptor tyrosine kinase EGFR. All family members heterodimerize with each other to activate downstream signalling pathways and are aberrantly expressed in many cancers, particularly forms of breast cancer.

  ----------------------------------------------------------------- --------------------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                                                      Common abbreviation   HGNC, UniProt   Endogenous ligands
  epidermal growth factor receptor                                  EGFR                  EGFR, P00533    amphiregulin (AREG, AREGB, P15514), betacellulin (BTC, P35070), EGF (EGF, P01133), epigen (EPGN, Q6UW88), epiregulin (EREG, O14944), HB-EGF (HBEGF, Q99075), TGFα (TGFA, P01135)
  v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3   HER3                  ERBB3, P21860   NRG-1 (NRG1, Q02297), NRG-2 (NRG2, O14511)
  v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4   HER4                  ERBB4, Q15303   betacellulin (BTC, P35070), epiregulin (EREG, O14944), HB-EGF (HBEGF, Q99075), NRG-1 (NRG1, Q02297), NRG-2 (NRG2, O14511), NRG-3 (NRG3, P56975), NRG-4 (NRG4, Q8WWG1)
  ----------------------------------------------------------------- --------------------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
--------

\[125I\]EGF (human) has been used to label the ErbB1 EGF receptor. The extracellular domain of ErbB2 can be targetted by the antibodies trastuzumab and pertuzumab to inhibit ErbB family action. The intracellular ATP-binding site of the tyrosine kinase domain can be inhibited by GW583340 (7.9--8.0, [@b63]), gefitinib, erlotinib and tyrphostins AG879 and AG1478.

Type II RTKs: Insulin receptor family
=====================================

Overview
--------

The circulating peptide hormones insulin (INS, P01308) and the related insulin-like growth factors (IGF) activate Class II receptor tyrosine kinases [@b65], to evoke cellular responses, mediated through multiple intracellular adaptor proteins. Exceptionally amongst the catalytic receptors, the functional receptor in the insulin receptor family is derived from a single gene product, cleaved post-translationally into two peptides, which then cross-link via disulphide bridges to form a heterotetramer. Intriguingly, the endogenous peptide ligands are formed in a parallel fashion with post-translational processing producing a heterodimer linked by disulphide bridges. Signalling through the receptors is mediated through a rapid autophosphorylation event at intracellular tyrosine residues, followed by recruitment of multiple adaptor proteins, notably IRS1 (P35568), IRS2 (Q9Y4H2), SHC1 (P29353), GRB2 (P62993) and SOS1 (Q07889).

Serum levels of free IGFs are kept low by the action of IGF binding proteins (IGFBP1-5, P08833, P18065, P17936, P22692, P24593), which sequester the IGFs; overexpression of IGFBPs may induce apoptosis, while IGFBP levels are also altered in some cancers.

  --------------------- ----------------------- ------------------------------------------ -----------------------------------
  Nomenclature          Insulin receptor        Insulin-like growth factor I               Insulin receptor-related receptor
  Common abbreviation   InsR                    IGF1R                                      IRR
  HGNC, UniProt         INSR, P06213            IGF1R, P08069                              INSRR, P14616
  Endogenous ligands    insulin (INS, P01308)   IGF1 (IGF1, P05019), IGF2 (IGF2, P01344)   --
  --------------------- ----------------------- ------------------------------------------ -----------------------------------

Comments
--------

There is evidence for low potency binding and activation of insulin receptors by IGF1. IGF2 also binds and activates the cation-independent mannose 6-phosphate receptor (also known as the insulin-like growth factor II receptor), which lacks classical signalling capacity and appears to subserve a trafficking role [@b72]. INSRR, which has a much more discrete localization, being predominant in the kidney [@b69], currently lacks a cognate ligand or evidence for functional impact.

Antibodies targetting IGF1, IGF2 and the extracellular portion of the IGF1 receptor are in clinical trials.

PQ401 inhibits the insulin-like growth factor receptor [@b56], while BMS-536924 inhibits both the insulin receptor and the insulin-like growth factor receptor [@b85].

Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
=====================================================

Overview
--------

Type III RTKs include PDGFR, CSF-1R (Ems), Kit and FLT3, which function as homo- or heterodimers. Endogenous ligands of PDGF receptors are homo- or heterodimeric: PDGFA, PDGFB, VEGFE and PDGFD combine as homo- or heterodimers to activate homo- or heterodimeric PDGF receptors. SCF is a dimeric ligand for KIT. Ligands for CSF1R are either monomeric or dimeric glycoproteins, while the endogenous agonist for FLT3 is a homodimer.

  --------------------- ------------------------------------------------------------ ----------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------------------
  Nomenclature          platelet-derived growth factor receptor, alpha polypeptide   platelet-derived growth factor receptor, beta polypeptide   v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog   colony stimulating factor 1 receptor                                fms-related tyrosine kinase 3
  Common abbreviation   PDGFRα                                                       PDGFRβ                                                      Kit                                                             CSFR                                                                FLT3
  HGNC, UniProt         PDGFRA, P16234                                               PDGFRB, P09619                                              KIT, P10721                                                     CSF1R, P07333                                                       FLT3, P36888
  Endogenous ligands    PDGF                                                         PDGF                                                        SCF (KITLG, P21583)                                             G-CSF (CSF3, P09919), GM-CSF (CSF2, P04141), M-CSF (CSF1, P09603)   FLT3L (FLT3LG, P49771)
  Comment               --                                                           --                                                          --                                                              --                                                                  5\'-fluoroindirubinoxime has been described as a selective FLT3 inhibitor [@b57]
  --------------------- ------------------------------------------------------------ ----------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------------------

Comments
--------

Various small molecular inhibitors of type III RTKs have been described, including imatinib and nilotinib (targetting PDGFR, KIT and CSF1R); midostaurin and AC220 (quizartinib; FLT3), as well as pan-type III RTK inhibitors such as sunitinib and sorafenib [@b78]; 5\'-fluoroindirubinoxime has been described as a selective FLT3 inhibitor [@b53].

Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family
=======================================================================

Overview
--------

VEGF receptors are homo- and heterodimeric proteins, which are characterized by seven Ig-like loops in their extracellular domains and a split kinase domain in the cytoplasmic region. They are key regulators of angiogenesis and lymphangiogenesis; as such, they have been the focus of drug discovery for conditions such as metastatic cancer. Splice variants of VEGFR1 and VEGFR2 generate truncated proteins limited to the extracellular domains, capable of homodimerisation and binding VEGF ligands as a soluble, non-signalling entity. Ligands at VEGF receptors are typically homodimeric. VEGFA (VEGFA, P15692) is able to activate VEGFR1 homodimers, VEGFR1/2 heterodimers and VEGFR2/3 heterodimers. VEGFB (VEGFB, P49765) and placental growth factor activate VEGFR1 homodimers, while VEGFC (VEGFC, P49767) and VEGFD (FIGF, O43915) activate VEGFR2/3 heterodimers and VEGFR3 homodimers, and, following proteolysis, VEGFR2 homodimers.

  --------------------- ---------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------
  Nomenclature          fms-related tyrosine kinase 1                  kinase insert domain receptor (a type III receptor tyrosine kinase)   fms-related tyrosine kinase 4
  Common abbreviation   VEGFR-1                                        VEGFR-2                                                               VEGFR-3
  HGNC, UniProt         FLT1, P17948                                   KDR, P35968                                                           FLT4, P35916
  Endogenous ligands    VEGFA (VEGFA, P15692), VEGFB (VEGFB, P49765)   VEGFA (VEGFA, P15692), VEGFC (VEGFC, P49767), VEGFE (PDGFC, Q9NRA1)   VEGFC (VEGFC, P49767), VEGFD (FIGF, O43915), VEGFE (PDGFC, Q9NRA1)
  --------------------- ---------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------

Comments
--------

The VEGFR, as well as VEGF ligands, have been targeted by antibodies and tyrosine kinase inhibitors. DMH4 [@b62], Ki8751 [@b68] and ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity [@b84] are described as VEGFR2-selective tyrosine kinase inhibitors. Bevacizumab is a monoclonal antibody directed against VEGF-A, used clinically for the treatment of certain metastatic cancers; an antibody fragment has been used for wet age-related macular degeneration.

Type V RTKs: FGF (fibroblast growth factor) receptor family
===========================================================

Overview
--------

Fibroblast growth factor (FGF) family receptors act as homo- and heterodimers, and are characterized by Ig-like loops in the extracellular domain, in which disulphide bridges may form across protein partners to allow the formation of covalent dimers which may be constitutively active. FGF receptors have been implicated in achondroplasia, angiogenesis and numerous congenital disorders. At least 22 members of the FGF gene family have been identified in the human genome [@b61]. Within this group, subfamilies of FGF may be divided into canonical, intracellular and hormone-like FGFs. FGF1-FGF10 have been identified to act through FGF receptors, while FGF11-14 appear to signal through intracellular targets. Other family members are less well characterized [@b83].

  --------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature          fibroblast growth factor receptor 1                                                                                     fibroblast growth factor receptor 2                                                                                                             fibroblast growth factor receptor 3                                                                                     fibroblast growth factor receptor 4
  Common abbreviation   FGFR1                                                                                                                   FGFR2                                                                                                                                           FGFR3                                                                                                                   FGFR4
  HGNC, UniProt         FGFR1, P11362                                                                                                           FGFR2, P21802                                                                                                                                   FGFR3, P22607                                                                                                           FGFR4, P22455
  Endogenous ligands    FGF-1 (FGF1, P05230), FGF-2 (FGF2, P09038), FGF-4 (FGF4, P08620) \> FGF-5 (FGF5, P12034), FGF-6 (FGF6, P10767) [@b77]   FGF-1 (FGF1, P05230) \> FGF-4 (FGF4, P08620), FGF-7 (FGF7, P21781), FGF-9 (FGF9, P31371) \> FGF-2 (FGF2, P09038), FGF-6 (FGF6, P10767) [@b77]   FGF-1 (FGF1, P05230), FGF-2 (FGF2, P09038), FGF-9 (FGF9, P31371) \> FGF-4 (FGF4, P08620), FGF-8 (FGF8, P55075) [@b77]   FGF-1 (FGF1, P05230), FGF-2 (FGF2, P09038), FGF-4 (FGF4, P08620), FGF-9 (FGF9, P31371) \> FGF-6 (FGF6, P10767), FGF-8 (FGF8, P55075) [@b77]
  --------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------

Comments
--------

Splice variation of the receptors can influence agonist responses. FGFRL1 (Q8N441) is a truncated kinase-null analogue.

Various antibodies and tyrosine kinase inhibitors have been developed against FGF receptors [@b71],[@b87]. PD161570 is an FGFR tyrosine kinase inhibitor [@b54], while PD173074 has been described to inhibit FGFR1 and FGFR3 [@b80].

Type VII RTKs: Neurotrophin receptor/Trk family
===============================================

Overview
--------

The neurotrophin receptor family of RTKs include trkA, trkB and trkC (tropomyosin-related kinase) receptors, which respond to NGF, BDNF and neurotrophin-3, respectively. They are associated primarily with proliferative and migration effects in neural systems. Various isoforms of neurotrophin receptors exist, including truncated forms of trkB and trkC, which lack catalytic domains. p75(TNFRSF16, also known as nerve growth factor receptor), which has homologies with tumour necrosis factor receptors, lacks a tyrosine kinase domain, but can signal via ceramide release and nuclear factor κB (NF-κB) activation. Both trkA and trkB contain two leucine-rich regions and can exist in monomeric or dimeric forms.

  --------------------- ------------------------------------------------ ----------------------------------------------------------------- ------------------------------------------------
  Nomenclature          neurotrophic tyrosine kinase, receptor, type 1   neurotrophic tyrosine kinase, receptor, type 2                    neurotrophic tyrosine kinase, receptor, type 3
  Common abbreviation   trkA                                             trkB                                                              trkC
  HGNC, UniProt         NTRK1, P04629                                    NTRK2, Q16620                                                     NTRK3, Q16288
  Endogenous ligands    NGF (NGF, P01138) \> NT-3 (NTF3, P20783)         BDNF (BDNF, P23560), NT-4 (NTF4, P34130) \> NT-3 (NTF3, P20783)   NT-3 (NTF3, P20783)
  --------------------- ------------------------------------------------ ----------------------------------------------------------------- ------------------------------------------------

Comments
--------

\[125I\]NGF (human) and \[125I\]BDNF have been used to label the trkA and trkB receptor, respectively. p75 influences the binding of NGF (NGF, P01138) and NT-3 (NTF3, P20783) to trkA. The ligand selectivity of p75 appears to be dependent on the cell type; for example, in sympathetic neurones, it binds NT-3 (NTF3, P20783) with comparable affinity to trkC [@b60].

Small molecule agonists of trkB have been described, including LM22A4 [@b73], while ANA12 has been described as a non- competitive antagonist of BDNF binding to trkB [@b56]. GNF5837 is a family-selective tyrosine kinase inhibitor [@b52], while the tyrosine kinase activity of the trkA receptor can be inhibited by GW441756 (p~IC~50= 8.7, [@b86]) and tyrphostin AG879 [@b76].

Type VIII RTKs: ROR family
==========================

Overview
--------

Members of the ROR family (ENSFM00510000502747) appear to be activated by ligands complexing with other cell-surface proteins. Thus, ROR1 and ROR2 appear to be activated by Wnt-5a (WNT5A, P41221) binding to a Frizzled receptor thereby forming a cell-surface multiprotein complex [@b67].

  --------------------- ------------------------------------------------- -------------------------------------------------
  Nomenclature          receptor tyrosine kinase-like orphan receptor 1   receptor tyrosine kinase-like orphan receptor 2
  Common abbreviation   ROR1                                              ROR2
  HGNC, UniProt         ROR1, Q01973                                      ROR2, Q01974
  --------------------- ------------------------------------------------- -------------------------------------------------

Type X RTKs: HGF (hepatocyte growth factor) receptor family
===========================================================

Overview
--------

HGF receptors regulate maturation of the liver in the embryo, as well as having roles in the adult, for example, in the innate immune system. HGF is synthesized as a single gene product, which is post-translationally processed to yield a heterodimer linked by a disulphide bridge. The maturation of HGF is enhanced by a serine protease, HGF activating complex, and inhibited by HGF-inhibitor 1, a serine protease inhibitor. MST1, the ligand of RON, is two disulphide-linked peptide chains generated by proteolysis of a single gene product.

  --------------------- -------------------- -------------------------------------------------------------------
  Nomenclature          met proto-oncogene   macrophage stimulating 1 receptor (c-met-related tyrosine kinase)
  Common abbreviation   Met                  Ron
  HGNC, UniProt         MET, P08581          MST1R, Q04912
  Endogenous ligands    HGF (HGF, P14210)    MST1 (MST1, P09603)
  --------------------- -------------------- -------------------------------------------------------------------

Comments
--------

PF04217903 is a selective Met tyrosine kinase inhibitor [@b58]. SU11274 is an inhibitor of the HGF receptor [@b79], with the possibility of further targets [@b53].

Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family
===========================================================

Overview
--------

Members of this RTK family (ENSFM00500000269872) represented a novel structural motif, when sequenced. The ligands for this family, Gas6 (GAS6, Q14393) and protein S (PROS1, P07225), are secreted plasma proteins which undergo vitamin K-dependent post-translational modifications generating carboxyglutamate-rich domains which are able to bind to negatively-charged surfaces of apoptotic cells.

  --------------------- -------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------
  Nomenclature          AXL receptor tyrosine kinase                                   TYRO3 protein tyrosine kinase                                  c-mer proto-oncogene tyrosine kinase
  Common abbreviation   Axl                                                            Tyro3                                                          Mer
  HGNC, UniProt         AXL, P30530                                                    TYRO3, Q06418                                                  MERTK, Q12866
  Endogenous ligands    Gas6 (GAS6, Q14393) [@b75], protein S (PROS1, P07225) [@b81]   Gas6 (GAS6, Q14393) [@b75], protein S (PROS1, P07225) [@b81]   Gas6 (GAS6, Q14393) [@b75]
  --------------------- -------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------

Comments
--------

AXL tyrosine kinase inhibitors have been described [@b74].

Type XII RTKs: TIE family of angiopoietin receptors
===================================================

Overview
--------

The TIE family were initially associated with formation of blood vessels. Endogenous ligands are angiopoietin-1 (ANGPT1, Q15389), angiopoietin-2 (ANGPT2, O15123), and angiopoietin-4 (ANGPT4, Q9Y264). angiopoietin-2 (ANGPT2, O15123) appears to act as an endogenous antagonist of angiopoietin-1 function.

  --------------------- ----------------------------------------------------------------- ------------------------------------------------------------------
  Nomenclature          tyrosine kinase with immunoglobulin-like and EGF-like domains 1   TEK tyrosine kinase, endothelial
  Common abbreviation   TIE1                                                              TIE2
  HGNC, UniProt         TIE1, P35590                                                      TEK, Q02763
  Endogenous ligands    --                                                                angiopoietin-1 (ANGPT1, Q15389), angiopoietin-4 (ANGPT4, Q9Y264)
  --------------------- ----------------------------------------------------------------- ------------------------------------------------------------------

Type XIII RTKs: Ephrin receptor family
======================================

Overview
--------

Ephrin receptors (ENSFM00250000000121) are a family of 15 RTKs (the largest family of RTKs) with two identified subfamilies (EphA and EphB), which have a role in the regulation of neuronal development, cell migration, patterning and angiogenesis. Their ligands are membrane-associated proteins, thought to be glycosylphosphatidylinositol-linked for EphA (EFNA1 (EFNA1, P20827), EFNA2 (EFNA2, O43921), EFNA3 (EFNA3, P52797), EFNA4 (EFNA4, P52798) and EFNA5 (EFNA5, P52803)) and 1TM proteins for Ephrin B (ENSFM00250000002014: EFNB1 (EFNB1, P98172), EFNB2 (EFNB2, P52799) and EFNB3 (EFNB3, Q15768)), although the relationship between ligands and receptors has been incompletely defined.

  --------------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ------------------ ----------------- ----------------- ----------------- ----------------- -----------------
  Nomenclature          EPH receptor A1   EPH receptor A2   EPH receptor A3   EPH receptor A4   EPH receptor A5   EPH receptor A6   EPH receptor A7   EPH receptor A8   EPH receptor A10   EPH receptor B1   EPH receptor B2   EPH receptor B3   EPH receptor B4   EPH receptor B6
  Common abbreviation   EphA1             EphA2             EphA3             EphA4             EphA5             EphA6             EphA7             EphA8             EphA10             EphB1             EphB2             EphB3             EphB4             EphB6
  HGNC, UniProt         EPHA1, P21709     EPHA2, P29317     EPHA3, P29320     EPHA4, P54764     EPHA5, P54756     EPHA6, Q9UF33     EPHA7, Q15375     EPHA8, P29322     EPHA10, Q5JZY3     EPHB1, P54762     EPHB2, P29323     EPHB3, P54753     EPHB4, P54760     EPHB6, O15197
  --------------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ------------------ ----------------- ----------------- ----------------- ----------------- -----------------

Type XVI RTKs: DDR (collagen receptor) family
=============================================

Overview
--------

Discoidin domain receptors 1 and 2 (DDR1 and DDR2) are structurally-related membrane protein tyrosine kinases activated by collagen. Collagen is probably the most abundant protein in man, with at least 29 families of genes encoding proteins, which undergo splice variation and post-translational processing, and may exist in monomeric or polymeric forms, producing a triple-stranded, twine-like structure. In man, principal family members include COL1A1 (COL1A1, P02452), COL2A1 (COL2A1, P02458), COL3A1 (COL3A1, P02461) and COL4A1 (COL4A1, P02462).

  --------------------- --------------------------------------------- ---------------------------------------------
  Nomenclature          discoidin domain receptor tyrosine kinase 1   discoidin domain receptor tyrosine kinase 2
  Common abbreviation   DDR1                                          DDR2
  HGNC, UniProt         DDR1, Q08345                                  DDR2, Q16832
  --------------------- --------------------------------------------- ---------------------------------------------

Comments
--------

The tyrosine kinase inhibitors of DDR, imatinib and nilotinib, were identified from proteomic analysis [@b59].

Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family
==============================================================

Overview
--------

The LTK family (ENSFM00500000270379) appear to lack endogenous ligands. LTK is subject to tissue-specific splice variation, which appears to generate products in distinct subcellular locations. Alk fusions derived from gene translocations are associated with large cell lymphomas and inflammatory myofibrilastic tumours.

  --------------------- ------------------------------------ --------------------------------------------------------------------------------------------------
  Nomenclature          leukocyte receptor tyrosine kinase   anaplastic lymphoma receptor tyrosine kinase
  Common abbreviation   LTK                                  ALK
  HGNC, UniProt         LTK, P29376                          ALK, Q9UM73
  Comment               --                                   crizotinib appears to be a selective ALK inhibitor acting on the tyrosine kinase activity [@b64]
  --------------------- ------------------------------------ --------------------------------------------------------------------------------------------------

Receptor tyrosine phosphatases (RTP)
====================================

Overview
--------

Receptor tyrosine phosphatases (RTP) are cell-surface proteins with a single TM region and intracellular phosphotyrosine phosphatase activity. Many family members exhibit constitutive activity in heterologous expression, dephosphorylating intracellular targets such as Src tyrosine kinase (SRC) to activate signalling cascades. Family members bind components of the extracellular matrix or cell-surface proteins indicating a role in intercellular communication.

  -------------- ---------------- ---------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt    Putative endogenous ligands
  RTP Type A     PTPRA, P18433    --
  RTP Type B     PTPRB, P23467    --
  RTP Type C     PTPRC, P08575    galectin-1 (LGALS1, P09382) [@b93]
  RTP Type D     PTPRD, P23468    netrin-G3 ligand (LRRC4B, Q9NT99) [@b90]
  RTP Type E     PTPRE, P23469    --
  RTP Type F     PTPRF, P10586    netrin-G3 ligand (LRRC4B, Q9NT99) [@b90]
  RTP Type G     PTPRG, P23470    contactin-3 (CNTN3, Q9P232), contactin-4 (CNTN4, Q8IWV2), contactin-5 (CNTN5, O94779), contactin-6 (CNTN6, Q9UQ52) [@b88]
  RTP Type H     PTPRH, Q9HD43    --
  RTP Type J     PTPRJ, Q12913    --
  RTP Type K     PTPRK, Q15262    galectin-3 (LGALS3, P17931), galectin-3 binding protein (LGALS3BP, Q08380) [@b89]
  RTP Type M     PTPRM, P28827    --
  RTP Type N     PTPRN, Q16849    --
  RTP Type N2    PTPRN2, Q92932   --
  RTP Type O     PTPRO, Q16827    --
  RTP Type Q     PTPRQ, Q9UMZ3    --
  RTP Type R     PTPRR, Q15256    --
  RTP Type S     PTPRS, Q13332    chondroitin sulphate proteoglycan 3 (NCAN, O14594), netrin-G3 ligand (LRRC4B, Q9NT99) [@b90],[@b92]
  RTP Type T     PTPRT, O14522    --
  RTP Type U     PTPRU, Q92729    --
  RTP Type Z1    PTPRZ1, P23471   contactin-1 (CNTN1, Q12860), pleiotrophin (PTN, C9JR52) (acts as a negative regulator) [@b88],[@b91]
  -------------- ---------------- ---------------------------------------------------------------------------------------------------------------------------

Tumour necrosis factor (TNF) receptor family
============================================

Overview
--------

The TNF receptor superfamily (TNFRSF, provisional nomenclature) displays limited homology beyond an extracellular domain rich in cysteine residues and is activated by at least 18 different human homologues of TNF referred to as the TNF superfamily (TNFSF). Some homologues lacking transmembrane and cytoplasmic domains function as decoy receptors binding ligand without inducing cell signalling. Many of these receptors and ligands function as multimeric entities. Signalling through these receptors is complex and involves interaction with cytoplasmic adaptor proteins (such as TRADD and TRAF1). Several of these receptors contain cytoplasmic motifs known as 'death domains', which upon activation serve to recruit death domain- and death effector domain-containing proteins crucial for the initiation of an apoptotic response. Additional signalling pathways include the regulation of the nuclear factor κB or mitogen-activated protein kinase pathways. Pharmacological manipulation of these receptors is mainly enacted through chelating the endogenous agonists with humanised monoclonal antibodies (*e.g*. infliximab or adalimumab) or recombinant fusion proteins of IgG and soluble receptors (*e.g.* etanercept). Some mutated forms of TNF ligands are capable of selecting for different receptor subtypes.

Receptors
=========

  ------------------------------------- ------------------------- --------------------- ------------------- ----------------------------------- ------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------
  Nomenclature                          Systematic nomenclature   Common abbreviation   HGNC, UniProt       Adaptor proteins                    Endogenous ligands                                                                   Comment
  tumor necrosis factor receptor 1      TNFRSF1A                  TNFR1                 TNFRSF1A, P19438    TRADD                               TNFSF1 (LTA, P01374), TNF membrane form (TNF, P01375), TNF shed form (TNF, P01375)   --
  tumor necrosis factor receptor 2      TNFRSF1B                  TNFR2                 TNFRSF1B, P20333    TRAF1, TRAF2, TRAF5                 TNFSF1 (LTA, P01374), TNF membrane form (TNF, P01375)                                --
  lymphotoxin β receptor                TNFRSF3                   --                    LTBR, P36941        TRAF3, TRAF4, TRAF5                 LIGHT (TNFSF14, O43557), lymphotoxin β2α1 heterotrimer (LTA, LTB, Q06643, P01374)    --
  OX40                                  TNFRSF4                   --                    TNFRSF4, P43489     TRAF1, TRAF2, TRAF3, TRAF5          OX-40 ligand (TNFSF4, P23510)                                                        --
  CD40                                  TNFRSF5                   --                    CD40, P25942        TRAF1, TRAF2, TRAF3, TRAF5, TRAF6   CD40 ligand (CD40LG, P29965)                                                         --
  Fas                                   TNFRSF6                   --                    FAS, P25445         FADD                                Fas ligand (FASLG, P48023)                                                           --
  CD27                                  TNFRSF7                   --                    CD27, P26842        TRAF2, SIVA                         CD70 (CD70, P32970)                                                                  --
  CD30                                  TNFRSF8                   --                    TNFRSF8, P28908     TRAF1, TRAF2, TRAF3, TRAF5          CD30 ligand (TNFSF8, P32971)                                                         --
  4-1BB                                 TNFRSF9                   --                    TNFRSF9, Q07011     TRAF1, TRAF2, TRAF3                 4-1BB ligand (TNFSF9, P41273)                                                        --
  death receptor 4                      TNFRSF10A                 DR4                   TNFRSF10A, O00220   FADD                                TRAIL (TNFSF10, P50591)                                                              --
  death receptor 5                      TNFRSF10B                 DR5                   TNFRSF10B, O14763   FADD                                TRAIL (TNFSF10, P50591)                                                              --
  receptor activator of NF-kappa B      TNFRSF11A                 RANK                  TNFRSF11A, Q9Y6Q6   TRAF1, TRAF2, TRAF3, TRAF5, TRAF6   RANK ligand (TNFSF11, O14788)                                                        --
  osteoprotegerin                       TNFRSF11B                 OPG                   TNFRSF11B, O00300   --                                  --                                                                                   Acts as a decoy receptor for RANK ligand (TNFSF11, O14788) and possibly for TRAIL (TNFSF10, P50591)
  death receptor 3                      TNFRSF25                  DR3                   TNFRSF25, Q93038    TRADD                               TL1A (TNFSF15, O95150)                                                               --
  TWEAK receptor                        TNFRSF12A                 --                    TNFRSF12A, Q9NP84   TRAF1, TRAF2, TRAF3                 TWEAK (TNFSF12, O43508)                                                              --
  TACI                                  TNFRSF13B                 --                    TNFRSF13B, O14836   TRAF2, TRAF5, TRAF6                 APRIL (TNFSF13, O75888), BAFF (TNFSF13B, Q9Y275)                                     --
  BAFF receptor                         TNFRSF13C                 BAFF-R                TNFRSF13C, Q96RJ3   TRAF3                               BAFF (TNFSF13B, Q9Y275)                                                              --
  herpes virus entry mediator           TNFRSF14                  HVEM                  TNFRSF14, Q92956    TRAF2, TRAF3, TRAF5                 BTLA (BTLA, Q7Z6A9), LIGHT (TNFSF14, O43557), TNFSF1 (LTA, P01374)                   --
  nerve growth factor receptor          TNFRSF16                  --                    NGFR, P08138        TRAF2, TRAF4, TRAF6                 BDNF (BDNF, P23560), NT-3 (NTF3, P20783), NT-4 (NTF4, P34130), NGF (NGF, P01138)     --
  B cell maturation antigen             TNFRSF17                  BCMA                  TNFRSF17, Q02223    TRAF1, TRAF2, TRAF3, TRAF5, TRAF6   APRIL (TNFSF13, O75888), BAFF (TNFSF13B, Q9Y275)                                     --
  glucocorticoid-induced TNF receptor   TNFRSF18                  GITR                  TNFRSF18, Q9Y5U5    TRAF1, TRAF2, TRAF3, SIVA           TL6 (TNFSF18, Q9UNG2)                                                                --
  toxicity and JNK inducer              TNFRSF19                  TAJ                   TNFRSF19, Q9NS68    TRAF1, TRAF2, TRAF3, TRAF5          TNFSF1 (LTA, P01374)                                                                 --
  RELT                                  TNFRSF19L                 --                    RELT, Q969Z4        TRAF1                               --                                                                                   --
  death receptor 6                      TNFRSF21                  DR6                   TNFRSF21, O75509    TRADD                               --                                                                                   --
  ectodysplasin A2 isoform receptor     TNFRS27                   --                    EDA2R, Q9HAV5       TRAF1, TRAF3, TRAF6                 ectodysplasin A2 (EDA, Q92838) [@b94]                                                --
  ------------------------------------- ------------------------- --------------------- ------------------- ----------------------------------- ------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------

Comments
========

TNFRSF1A is preferentially activated by the shed form of TNF ligand, whereas the membrane-bound form of TNF serves to activate TNFRSF1A and TNFRSF1B equally. The neurotrophins nerve growth factor (NGF (NGF, P01138), P01138), brain-derived neurotrophic factor (BDNF (BDNF, P23560), P23560), NT-3 (NTF3, P20783) (NTF3, P20783) and NT-4 (NTF4, P34130) (NTF4, P34130) are structurally unrelated to the TNF ligand superfamily but exert some of their actions through the "low affinity nerve growth factor receptor" (NGFR (TNFRSF16)) as well as through the TRK family of receptor tyrosine kinases. The endogenous ligands for EDAR and EDA2R are, respectively, the membrane (Q92838\[1-391\]) and secreted (Q92838\[160-391\]) isoforms of Ectodysplasin-A (EDA, Q92838).
